Genentech Says FDA Approves Venclexta Plus Gazyva for Chronic Lymphocytic Leukemia
May 15 2019 - 3:30PM
Dow Jones News
By Michael Dabaie
Roche Group's (RHHBY) Genentech said the U.S. Food and Drug
Administration approved Venclexta in combination with Gazyva for
the treatment of people with previously untreated chronic
lymphocytic leukemia or small lymphocytic lymphoma.
Venclexta is being developed by AbbVie Inc. (ABBV) and
Genentech.
The approval is based on the results of the randomized Phase III
CLL14 study. Fixed 12-month treatment with Venclexta plus Gazyva
significantly reduced the risk of disease progression or death by
67% compared to a current standard of care, Genentech said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
May 15, 2019 15:15 ET (19:15 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2024 to Jul 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jul 2023 to Jul 2024